JAK3 and acute lymphoblastic leukemia: In the post-tofacitinib sample, the frequency of the JAK3 p.M511I allele increased from 33% to 93%, and the frequency of the JAK3 p.V657W also increased from 37% to 97% in the T-ALL cells.